Difficulty: Medium
Average Score: 66%
Practice
A 47-year-old immigrant from Japan with a long history of untreated gastric ulcers develops stomach cancer. One drug in his initial treatment regimen is 5-fluorouracil (5-FU) as well as ondansetron to control nausea. While receiving this drug, the patient develops redness and numbness on the palms of his hands and soles of his feet. How can this reaction be avoided?
Correct answer
C
Rationale
In this scenario, the correct answer is to give 5-fluorouracil (5-FU) by continuous infusion (Option C) to avoid the development of redness and numbness on the palms of the hands and soles of the feet, known as hand-foot syndrome.
Giving 5-FU by continuous infusion allows for a more consistent and controlled delivery of the drug, which can help reduce the incidence and severity of hand-foot syndrome. When 5-FU is given as a bolus (Option B), it can lead to higher peak concentrations that may contribute to increased toxicity and side effects.
Regarding the other options:
- Option A (Do not coadminister ondansetron with 5-FU) is not the correct approach because ondansetron is used to control nausea and vomiting, which are common side effects of 5-FU treatment. Ondansetron does not directly contribute to hand-foot syndrome.
- Option D (Give with leucovorin) is not directly related to preventing hand-foot syndrome. Leucovorin is often given with 5-FU to enhance its effectiveness in treating certain cancers but does not specifically address the side effect of hand-foot syndrome.
Educationally, it is crucial for healthcare providers to understand the rationale behind the choice of drug administration regimens to optimize patient outcomes and minimize adverse effects. Teaching about the importance of continuous infusion of 5-FU in managing hand-foot syndrome can improve patient care and safety in oncology practice.
Giving 5-FU by continuous infusion allows for a more consistent and controlled delivery of the drug, which can help reduce the incidence and severity of hand-foot syndrome. When 5-FU is given as a bolus (Option B), it can lead to higher peak concentrations that may contribute to increased toxicity and side effects.
Regarding the other options:
- Option A (Do not coadminister ondansetron with 5-FU) is not the correct approach because ondansetron is used to control nausea and vomiting, which are common side effects of 5-FU treatment. Ondansetron does not directly contribute to hand-foot syndrome.
- Option D (Give with leucovorin) is not directly related to preventing hand-foot syndrome. Leucovorin is often given with 5-FU to enhance its effectiveness in treating certain cancers but does not specifically address the side effect of hand-foot syndrome.
Educationally, it is crucial for healthcare providers to understand the rationale behind the choice of drug administration regimens to optimize patient outcomes and minimize adverse effects. Teaching about the importance of continuous infusion of 5-FU in managing hand-foot syndrome can improve patient care and safety in oncology practice.